The health insurer's shares soar in reaction, with a federal probe into its Medicaid business ongoing.

The health insurer's shares soar after it names two new executives following a federal investigation into its Medicaid business.

Merck and Schering-Plough release a defense of their dealings on the drug. Critics see more problems.

Expert committees might have kept Schering and Merck out of trouble. Congress is asking why they weren't there.

Schering and Merck may not be as villainous as critics claim. For investors, it may not matter.